Value
3.0/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 1.3 |
| P/S | 4.4 |
| Fwd P/E | 2.3 |
| PEG | 3.1 |
| Analyst target | 4.0 |
- ▸Forward P/E: 50.8x
- ▸PEG: 4.08
PEN · Why this verdict
Why Penumbra (PEN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With the stock at $318.21 and analyst resistance at $323.08, there is only 1.5% upside remaining while downside to stop-loss is 1.8%, providing a reward-to-risk ratio of less than 1 and no margin of safety at current prices. Warnings | Analyst targets are revised upward above $360 within 12 months, restoring at least a 10% upside case. | →Stable |
| CounterPrice resistance targets are dynamic and can be reset quickly by new analyst coverage or positive clinical data; the current 1.5% gap may be a temporary ceiling rather than a permanent cap. | ||
Penumbra holds a wide economic moat score of 8.4 in its thrombectomy device niche, with a Piotroski F-Score of 8/9 and compounder-grade quality metrics, suggesting durable structural competitive advantages in a specialized medical device segment. Quality breakdown | Moat score remains above 8.0 and Piotroski F-Score stays at 7 or above over the next 12 months as the company maintains market position. | →Stable |
| CounterThe company has a documented concentration risk in thrombectomy products, meaning the moat is narrow in breadth; a competitor breakthrough in this specific area could erode the entire moat simultaneously. | ||
Penumbra has beaten EPS estimates in 3 of the last 4 quarters, including outperformance of $0.97 versus $0.92 and $1.18 versus $1.11, demonstrating consistent operational execution. Earnings | EPS beats continue in at least 3 of the next 4 quarters with average positive surprise above 4%. | →Stable |
| CounterThe one miss in the most recent quarter was -4.6%, and average surprise across all 4 quarters is only 2.9%, showing the beat margin is thin and vulnerable to small estimate changes. | ||
Penumbra faces two high-concentration risks: dependency on thrombectomy products for the majority of revenue and reliance on a single or limited number of suppliers, creating vulnerabilities on both the demand and supply sides. Bear case | The company diversifies revenue such that thrombectomy products account for less than 60% of total revenue within 24 months. | →Stable |
| CounterFocus on a single high-growth, high-margin device category has historically been a strategic advantage for medical device companies; diversification risk may be greater than concentration risk for a specialist company. | ||
With the stock at $318.21 and analyst resistance at $323.08, there is only 1.5% upside remaining while downside to stop-loss is 1.8%, providing a reward-to-risk ratio of less than 1 and no margin of safety at current prices.
→StableWarnings
- Expectation
- Analyst targets are revised upward above $360 within 12 months, restoring at least a 10% upside case.
CounterPrice resistance targets are dynamic and can be reset quickly by new analyst coverage or positive clinical data; the current 1.5% gap may be a temporary ceiling rather than a permanent cap.
Penumbra holds a wide economic moat score of 8.4 in its thrombectomy device niche, with a Piotroski F-Score of 8/9 and compounder-grade quality metrics, suggesting durable structural competitive advantages in a specialized medical device segment.
→StableQuality breakdown
- Expectation
- Moat score remains above 8.0 and Piotroski F-Score stays at 7 or above over the next 12 months as the company maintains market position.
CounterThe company has a documented concentration risk in thrombectomy products, meaning the moat is narrow in breadth; a competitor breakthrough in this specific area could erode the entire moat simultaneously.
Penumbra has beaten EPS estimates in 3 of the last 4 quarters, including outperformance of $0.97 versus $0.92 and $1.18 versus $1.11, demonstrating consistent operational execution.
→StableEarnings
- Expectation
- EPS beats continue in at least 3 of the next 4 quarters with average positive surprise above 4%.
CounterThe one miss in the most recent quarter was -4.6%, and average surprise across all 4 quarters is only 2.9%, showing the beat margin is thin and vulnerable to small estimate changes.
Penumbra faces two high-concentration risks: dependency on thrombectomy products for the majority of revenue and reliance on a single or limited number of suppliers, creating vulnerabilities on both the demand and supply sides.
→StableBear case
- Expectation
- The company diversifies revenue such that thrombectomy products account for less than 60% of total revenue within 24 months.
CounterFocus on a single high-growth, high-margin device category has historically been a strategic advantage for medical device companies; diversification risk may be greater than concentration risk for a specialist company.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Penumbra holds a wide economic moat in thrombectomy medical devices with a strong Piotroski F-Score of 8/9 and 3 recent earnings beats, but the stock has reached analyst targets with effectively zero upside remaining and is concentrated in a single product line with limited-supplier dependency.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.2 |
| ROA | 4.5 |
| Gross margin | 9.5 |
| Op margin | 4.1 |
| Net margin | 5.9 |
| Current ratio | 7.0 |
| FCF quality | 6.1 |
| Moat | 8.4 |
| Rule of 40 | 5.5 |
| Piotroski F | 8.9 |
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Strong Piotroski F-Score: 8/9
Growth
3.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.4 |
| EPS growth | 0.0 |
Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 1.4 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 7.0 |
| erm sentiment | 4.2 |
Insider
5.1/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.2 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.1 |
| quality rank | 7.6 |
| growth rank | 6.3 |
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.1 |
| support resistance | 5.5 |
| 52w position | 7.6 |
Risk (lower is worse)
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 6.1 |
| volatility | 10.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 8.8 |
| debt equity | 9.4 |
- ▸Elevated put/call: 3.59
- ▸High IV: 82%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 3.9 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.8>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:23d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.0=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.03
Upside
-0.5%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 51 mid-range, Bollinger mid-band
EdgeCatalyst-Driven — Earnings in 23d with 3/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.8 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 6.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.0=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.03 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 6.8, Quality at 6.4, and Risk (lower is worse) at 5.9; the weakest are Value at 3.0, Growth at 3.2, and Peer rank at 3.7. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.03 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Thrombectomy
Trip ifPiotroski F-Score falls below 6 in the next annual report, indicating deterioration in 3 or more financial health metrics.
- P2Earnings Beat Medical Device
Trip ifEPS falls below $0.85 per quarter for 2 consecutive quarters, indicating operational deterioration below the recent $0.97-$1.18 delivery range.
- P3Product Supplier Concentration
Trip ifA single key supplier disruption causes more than 6 months of production delay, disclosed in regulatory filings or press releases.
- P4Target Reached No Upside
Trip ifAnalyst consensus price target falls below $280, reducing implied upside to less than 0% from current levels and signaling a fundamental downgrade cycle.